Therapeutic area intelligence for Basal Cell Carcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Feldan Therapeutics →

Assets

Feldan →

Recent signals(1)

ClinicalJuly 21, 2026

Feldan Therapeutics Initiates FLD-103 Trial for Basal Cell Carcinoma

Feldan Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and efficacy of intralesional FLD-103 in patients with Basal Cell Carcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Basal Cell Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.